Radboud University Medical Centre
Nijmegen, Gelderland, 6525GA, Netherlands
NCT Number: NCT05191498
This is a feasibility study in which patients with pancreatic cancer are treated with intratumoral holmium microsphere injections.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Nijmegen, Gelderland, 6525GA, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
i. 1o-90o contact between tumor and the superior mesenteric artery, celiac axis or common hepatic artery. Or; ii. 90o-270o contact between tumor and superior mesenteric vein or portal vein, without occlusion.
iii. The discussion on resectability has to be made in consensus at multidisciplinary meetings/discussions and may overrule the above criteria (i, ii).
Exclusion criteria
Intratumoral injection of QuiremSpheres® up to a dose of 150 Gy.
Time frame: At 1 week after intervention
To establish the feasibility of intratumoral implantation of QuiremSpheres® by evaluating the average tumour absorbed dose in Gy calculated on SPECT.
Time frame: At 1 week after intervention
Microsphere distribution in analysed using MRI to evaluate tumour absorbed and non-target absorbed dose.
Time frame: At 1 week after intervention
Microsphere distribution in analysed using CT to evaluate tumour absorbed and non-target absorbed dose.
Time frame: Up to 3 months after intervention
Safety, expressed in Common Terminology Criteria for Adverse Events, grade 3 and higher, probably or definitely related to the implantation procedure or medical device implant is monitored up to 3 months after intervention.
Time frame: At 3 months after intervention
Tumor response to the intervention is evaluated according to the Response evaluation criteria in solid tumors (RECIST) version 1.1 after 3 months.
Looking for future studies?
Notify MeRadboud University Medical Center
Other
Intratumoral Holmium Microspheres Brachytherapy for Patients With Pancreatic Cancer; a Single Center, Non-randomized, Feasibility Study in an Open Surgical Setting - the SLOTH1 Study
Acronym: SLOTH-1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04512209
Abdominal Neoplasms, Adnexal Diseases
Ghent, Belgium
View Trial DetailsNCT02206360
BRCA 1/2, Colonic Diseases
White Plains, New York, United States
View Trial DetailsNCT04902872
Adnexal Diseases, Appendiceal Neoplasms
New Haven, Connecticut, United States
View Trial DetailsNCT04851106
Digestive System Diseases, Digestive System Neoplasms
Lyon, France
View Trial Details